Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)

Cosette Pharmaceuticals acquires Intrarosa from Endoceutics

Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product

Unichem receives ANDA approval for Prasugrel Tablets

Prasugrel tablets are indicated to reduce the rate of thrombotic CV events

Lupin receives approval from USFDA for Prasugrel Tablets, USP

Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products

As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio